Pre‑initiation Assessment

Obtain urgent brain imaging (CT or MRI) to rule out intracranial hemorrhage before any antiplatelet therapy is started. 1, 2
Perform formal dysphagia screening to determine the safest route of medication administration. 1
Exclude cardioembolic sources (e.g., atrial fibrillation, cardiac thrombus) to confirm a non‑cardioembolic etiology that warrants antiplatelet rather than anticoagulant therapy. 1, 2

Managing the Bleeding Complication

Active bleeding is a relative contraindication to initiating dual antiplatelet therapy (DAPT); the bleeding source must be controlled first. 1, 3
Obtain an urgent urology consultation to identify and treat the source of hematuria. 4
Serially monitor hemoglobin and hematocrit to quantify bleeding severity. 4
If bleeding is minor and the risk of recurrent stroke is very high, use aspirin monotherapy as a bridge (loading 160‑325 mg, then 81‑325 mg daily) because it offers stroke protection with lower bleeding risk than DAPT. 1, 2

Timing and Efficacy of DAPT

DAPT provides maximal benefit when started within 12–24 hours of symptom onset; efficacy declines sharply after 24 hours. 1
Initiation beyond 72 hours yields minimal additional benefit because the highest risk for recurrent stroke occurs in the first 48–72 hours. (Evidence from trial timing analyses.)

DAPT Loading and Maintenance Protocol (once bleeding is controlled)

Loading doses – Aspirin 160‑325 mg orally (minimum 160 mg per Canadian stroke guidelines) and clopidogrel 300‑600 mg orally (300 mg based on the CHANCE trial; 600 mg based on the POINT trial). 1
Maintenance therapy – Aspirin 81 mg daily plus clopidogrel 75 mg daily for exactly 21‑30 days, after which therapy should be switched to single‑agent antiplatelet treatment. 1, 2
Alternative administration – If dysphagia is present, deliver aspirin 81 mg and clopidogrel 75 mg via enteral tube; if enteral access is unavailable, a rectal aspirin 325 mg suppository may be used. 1

Bleeding‑Risk Monitoring During DAPT

Major bleeding occurs in 0.9 % of patients receiving DAPT versus 0.4 % with monotherapy over the 21‑30‑day course. 1
This translates to an absolute increase of ~5 major bleeds per 1,000 patients treated, while preventing approximately 15 ischemic strokes per 1,000 patients. 1
Provide gastrointestinal protection (e.g., a proton‑pump inhibitor) given the recent bleeding history. 1
Continue close surveillance for recurrent hematuria, gastrointestinal bleeding, or intracranial hemorrhage. 1

Risk Stratification for Initiating DAPT

Use an ABCD² score ≥ 4 (or NIHSS 0‑3 for a minor stroke) to identify high‑risk TIA patients who benefit from DAPT. 1, 2
Confirm a non‑cardioembolic mechanism (no atrial fibrillation or cardiac thrombus). 1, 2
Aim to start therapy within < 24 hours of symptom onset; the latest acceptable window for proven benefit is ≤ 72 hours. 1

Pitfalls and Contraindications

Do not start DAPT while active, uncontrolled bleeding persists; the bleeding source must be addressed first. 3
Do not extend DAPT beyond 30 days, as the relative risk of major bleeding rises (RR 2.20‑2.48) without additional stroke‑prevention benefit. 1
Do not omit loading doses even if initiation is delayed; rapid platelet inhibition remains essential. 1
Do not use ticagrelor‑aspirin in bleeding‑prone patients; clopidogrel‑aspirin has a more favorable bleeding profile. 1, 2
If a major bleed occurs while on DAPT, promptly reassess and discontinue one or both agents. 1, 3

Transition to Long‑Term Therapy

After completing 21‑30 days of DAPT, switch to indefinite single‑antiplatelet therapy (aspirin 81‑325 mg daily, clopidogrel 75 mg daily, or aspirin‑dipyridamole). 1, 2
Clearly counsel the patient that dual therapy is temporary and must be stopped at the 21‑30‑day mark. 1

Alternative Approach When Bleeding Cannot Be Controlled

If hematuria persists beyond 72 hours from TIA onset, adopt indefinite aspirin monotherapy (81‑325 mg daily); evidence for DAPT beyond this window is lacking and bleeding risk outweighs uncertain benefit. 1, 2
Recognize that the DAPT window has closed and focus on aggressive risk‑factor modification together with single‑agent antiplatelet therapy. 2

Dual Antiplatelet Therapy for High‑Risk TIA and Minor Stroke

Patient Selection

Patients with a high‑risk transient ischemic attack (ABCD² score ≥ 4) should receive dual antiplatelet therapy (DAPT). [World Stroke Organization guideline – strong recommendation] 5
Patients with a minor ischemic stroke (NIHSS ≤ 3) are candidates for DAPT. 5
Patients with a mild‑moderate ischemic stroke (NIHSS ≤ 5) may also be treated with DAPT. 5
DAPT is indicated only for non‑cardioembolic etiologies; patients requiring anticoagulation (e.g., atrial fibrillation) should not receive DAPT. 5

Dosing Regimens

Aspirin + Clopidogrel (preferred)

Loading: Aspirin 160–325 mg + Clopidogrel 300–600 mg administered once. 5
Maintenance: Aspirin 81 mg daily + Clopidogrel 75 mg daily. 5
Duration: Continue for 21–30 days, then switch to a single antiplatelet agent. 5

Aspirin + Ticagrelor (alternative)

Loading: Aspirin 300–325 mg + Ticagrelor 180 mg once. 5
Maintenance: Aspirin 75–100 mg daily + Ticagrelor 90 mg twice daily. 5
Duration: Continue for 30 days, then transition to monotherapy. 5

Timing of Initiation

The greatest benefit is achieved when DAPT is started within 24 hours of symptom onset; initiation within 12–24 hours is strongly endorsed. [World Stroke Organization guideline – strong recommendation] 5
Canadian guidelines specify initiation within 24 hours, ideally within 12 hours. [Canadian Stroke Best Practice guideline – strong recommendation] 6

Efficacy Evidence

Early DAPT reduces the 90‑day risk of recurrent ischemic stroke by 32% (relative risk 0.68). [Class I, Level A evidence] 7

Bleeding Risk

Short‑term DAPT (21–30 days) modestly increases major bleeding (relative risk 2.22–2.48). [Class IIa, Level B evidence] 7
In trials of 21–30 day DAPT, extracranial bleeding occurred in 0.3–0.9% of patients versus 0.3–0.4% with monotherapy. 6
Prolonged DAPT (> 90 days) is discouraged because bleeding risk outweighs benefit. 8

Mandatory Prerequisites Before Initiation

Exclude intracranial hemorrhage with CT or MRI. 5
Verify a non‑cardioembolic source (no atrial fibrillation or other indication for anticoagulation). 5
Assess for dysphagia to determine the appropriate route of drug administration. 6

Special Clinical Situations

Post‑thrombolysis

Delay DAPT until a 24‑hour post‑thrombolysis scan confirms absence of intracranial hemorrhage. 6

Dysphagia

Administer aspirin 81 mg + clopidogrel 75 mg via enteral tube, or use an aspirin 325 mg rectal suppository when oral intake is not possible. 9

Planned urgent carotid revascularization

Consider aspirin monotherapy instead of DAPT to minimize peri‑operative bleeding risk. 6

Transition to Long‑Term Therapy

After 21–30 days of DAPT, switch to indefinite single‑antiplatelet therapy (aspirin, clopidogrel, or aspirin + extended‑release dipyridamole). 5

Common Pitfalls to Avoid

Do not extend DAPT beyond 90 days in routine practice; the incremental bleeding risk is not offset by additional stroke prevention. 8
Do not withhold DAPT beyond 24 hours when feasible, as efficacy declines rapidly after this window. 5
Do not use DAPT in patients who require anticoagulation for cardioembolic sources. 5
Do not omit loading doses; both aspirin and the second antiplatelet agent need a loading dose for rapid platelet inhibition. 5

Duration and Initiation of Dual Antiplatelet Therapy After Minor Non‑Cardioembolic Ischemic Stroke

Patient Selection Criteria

Patients with a minor non‑cardioembolic ischemic stroke (NIHSS ≤ 3) or a high‑risk TIA (ABCD² ≥ 4) should be considered for dual antiplatelet therapy (DAPT) 【10】.
Stroke severity must be confirmed as NIHSS ≤ 3 (or ≤ 5 when using aspirin‑ticagrelor) before DAPT initiation 【10】.
High‑risk TIA is defined by an ABCD² score ≥ 4 【10】.
An non‑cardioembolic etiology must be verified; atrial fibrillation, cardiac thrombus, or other indications for anticoagulation are exclusion criteria 【10】.
Intracranial hemorrhage must be excluded by CT or MRI before starting antiplatelet agents 【10】.

Recommended DAPT Regimens and Duration

Aspirin + Clopidogrel (Preferred)

Loading: Aspirin 160–325 mg + Clopidogrel 300 mg (CHANCE trial) or 600 mg (POINT trial) 【10】.
Maintenance: Aspirin 81 mg daily + Clopidogrel 75 mg daily 【10】.
Duration: 21 days of DAPT, as supported by the CHANCE trial and World Stroke Organization (WSO) guidelines 【10】.

Aspirin + Ticagrelor (Alternative)

Loading: Aspirin 300–325 mg + Ticagrelor 180 mg 【10】.
Maintenance: Aspirin 75–100 mg daily + Ticagrelor 90 mg twice daily 【10】.
Duration: 30 days of DAPT 【10】.

Critical Timing Window

DAPT should be started within 24 hours of symptom onset, ideally within 12 hours, to achieve maximal benefit 【10】.

Efficacy and Safety Outcomes

A 21‑day DAPT course reduces 90‑day recurrent ischemic stroke by 32 % (relative risk 0.68) compared with single‑antiplatelet therapy 【11】.
Short‑term DAPT (≤30 days) prevents ≈15 ischemic strokes per 1,000 patients treated 【12】【11】.
Extending DAPT beyond 90 days increases major bleeding risk (RR 2.20–2.48) without additional stroke‑prevention benefit 【11】.
Over a 21–30 day course, major bleeding occurs in 0.9 % of DAPT patients versus 0.4 % with monotherapy (≈5 extra major bleeds per 1,000 patients) 【12】.

Mandatory Transition to Single Antiplatelet Therapy

After completing 21–30 days of DAPT, patients must switch to indefinite single‑antiplatelet therapy 【10】.
Acceptable long‑term monotherapy options include:
- Aspirin 81–325 mg daily 【10】.
- Clopidogrel 75 mg daily 【10】.
- Aspirin 25 mg + extended‑release dipyridamole 200 mg twice daily 【10】.
Patients should be counseled explicitly that dual therapy is temporary and must stop at 21–30 days 【12】.

Special Clinical Situations

Post‑thrombolysis: Delay DAPT initiation until 24 hours after thrombolysis and confirm absence of intracranial hemorrhage on imaging 【12】; then follow the standard DAPT protocol 【12】.
Dysphagia: Administer aspirin 81 mg + clopidogrel 75 mg via an enteral tube 【10】; if enteral access is unavailable, a rectal aspirin 325 mg suppository may be used 【10】.
Intracranial atherosclerotic stenosis (50–99 %): DAPT is appropriate, and extension up to 90 days can be considered for this subgroup 【13】.

Contra‑indications and Pitfalls

Do NOT extend DAPT beyond 30 days in routine practice; bleeding risk outweighs any uncertain benefit 【11】.
Do NOT use DAPT in patients requiring anticoagulation for cardioembolic sources (e.g., atrial fibrillation) 【10】.
Do NOT omit loading doses; both aspirin and the second antiplatelet agent need loading for rapid platelet inhibition 【10】.

Monitoring During DAPT

Monitor for signs of intracranial hemorrhage, gastrointestinal bleeding, or other major bleeding while on DAPT 【12】.

Strength of Evidence

The 2023 World Stroke Organization (WSO) guidelines give a strong Class I, Level A recommendation for a 21‑day aspirin‑clopidogrel DAPT regimen in minor stroke/high‑risk TIA 【10】.
The 2018 Canadian Stroke Best Practice guidelines also endorse a 21–30 day DAPT course with Level A evidence 【12】.
The 2021 American Heart Association (AHA) guidelines support early short‑term DAPT based on the POINT and CHANCE trials 【13】【11】.

Dual Antiplatelet Therapy for Minor Ischemic Stroke and High‑Risk TIA

Patient Selection & Pre‑Treatment Requirements

DAPT is indicated for patients with minor ischemic stroke (NIHSS ≤ 3) or high‑risk TIA (ABCD² ≥ 4) when a non‑cardioembolic mechanism has been confirmed. The American Heart Association/American Stroke Association (AHA/ASA) recommends these criteria. 14
Before initiating DAPT, intracranial hemorrhage must be excluded by CT or MRI. 14

Timing of Initiation

Start DAPT within 12–24 hours of symptom onset (ideally within 12 h) to achieve maximal benefit; efficacy declines sharply after 24 h. 14

Dosing Regimens

Aspirin + Clopidogrel (Preferred)

Loading doses: Aspirin 160–325 mg orally once; Clopidogrel 300 mg (CHANCE protocol) or 600 mg (POINT protocol) orally once. 14
Maintenance doses: Aspirin 81 mg daily + Clopidogrel 75 mg daily. 14

Duration of Dual Therapy

Recommended duration: 21 days (based on the CHANCE trial) with a maximum of 30 days; extending beyond 30 days raises major‑bleeding risk from 0.4 % to 0.9 % without additional stroke‑prevention benefit. 14

Efficacy & Safety

Stroke recurrence: DAPT reduces 90‑day recurrent ischemic stroke by 32 % (relative risk 0.68) compared with aspirin alone, preventing roughly 15 strokes per 1,000 patients treated. 14
CHANCE trial data: At 90 days, stroke occurred in 8.2 % of patients receiving DAPT versus 11.7 % with aspirin alone (hazard ratio 0.68, p < 0.001). 14
Major bleeding: Adding clopidogrel increases major bleeding from 0.4 % (aspirin alone) to 0.9 % (≈5 extra major bleeds per 1,000 patients). 14
POINT trial data: Major hemorrhage was 0.9 % with DAPT versus 0.4 % with aspirin (hazard ratio 2.32, p = 0.02). 14

Transition to Long‑Term Therapy

After completing 21–30 days of DAPT, switch immediately to indefinite single‑antiplatelet therapy. 14
Preferred long‑term agent: Clopidogrel 75 mg daily, which is superior to aspirin for secondary prevention. 15
Acceptable alternatives: Aspirin 81–325 mg daily or aspirin 25 mg + extended‑release dipyridamole 200 mg twice daily. 15

Special Clinical Situations

Patients already on aspirin at stroke onset: Continue the existing aspirin dose and add clopidogrel loading (300 mg or 600 mg) and maintenance (75 mg daily); there is no evidence that increasing the aspirin dose improves outcomes. 16

Contraindications & Pitfalls

Absolute contraindications: Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage), cardioembolic stroke requiring anticoagulation, and hypersensitivity to clopidogrel or aspirin. 14
Pitfall – duration: Do not extend DAPT beyond 30 days in routine practice; the incremental bleeding risk outweighs uncertain benefit. 14
Pitfall – inappropriate use: Do not use DAPT in patients who need anticoagulation for cardioembolic sources. 14
Pitfall – imaging: Do not start antiplatelet therapy before neuroimaging confirms absence of intracranial hemorrhage. 14

Initiation and Management of Dual Antiplatelet Therapy after High‑Risk Transient Ischemic Attack

Patient Selection

High‑risk TIA is defined by an ABCD² score ≥ 4, which identifies patients at greatest risk of early recurrent stroke【17】.
Patients must have a non‑cardioembolic etiology; atrial fibrillation, cardiac thrombus, or any indication for anticoagulation are exclusion criteria【17】.
Intracranial hemorrhage must be excluded with urgent CT or MRI before any antiplatelet therapy is started【17】.
A dysphagia screen must be passed to ensure safe oral medication administration【17】.

Timing of Initiation

The optimal window for starting aspirin + clopidogrel is within 12 hours of symptom onset for maximal benefit【17】.
Initiation up to 24 hours after onset remains acceptable, though efficacy begins to decline【17】.
Starting DAPT within 12–24 hours prevents approximately 15 ischemic strokes per 1,000 patients treated【17】.

Loading and Maintenance Dosing

Loading (Day 1): Aspirin 160–325 mg orally (minimum 160 mg per Canadian guidelines)【17】.
Loading (Day 1): Clopidogrel 300 mg (CHANCE protocol) or 600 mg (POINT protocol) orally【17】.
Maintenance (Days 2–21/30): Aspirin 81 mg daily【17】.
Maintenance (Days 2–21/30): Clopidogrel 75 mg daily【17】.

Duration of Dual Therapy

The optimal DAPT duration is 21 days, with a maximum of 30 days【17】.
In the CHANCE trial, a 21‑day regimen reduced 90‑day stroke risk by 32 % (RR 0.68) with extracranial bleeding rates identical (0.3 %) in both groups【17】.
Extending DAPT to 90 days (POINT trial) increased major bleeding from 0.4 % to 0.9 % without additional stroke protection beyond the first 21 days【17】.
Pooled analyses confirm that benefit is confined to the first 21 days; no efficacy is observed from day 22 to day 90【17】.
Extending therapy beyond 30 days raises major‑bleeding risk (RR 2.20–2.48) without offsetting benefit【17】.

Transition to Long‑Term Monotherapy

After completing 21–30 days of DAPT, switch immediately to a single antiplatelet agent; both drugs should not be continued together【17】.
Acceptable long‑term options include aspirin 81–325 mg daily or aspirin 25 mg + extended‑release dipyridamole 200 mg twice daily【17】.
Patients should be explicitly counseled that dual therapy is temporary and must stop at 21–30 days【17】.

Special Clinical Situations

Post‑thrombolysis: Delay DAPT until ≥ 24 hours after IV alteplase and obtain a 24‑hour post‑thrombolysis scan to exclude intracranial hemorrhage before starting antiplatelet therapy【17】.
Dysphagia: Administer aspirin 81 mg and clopidogrel 75 mg via an enteral tube; if enteral access is unavailable, use an aspirin 325 mg rectal suppository【17】.
Planned urgent carotid revascularization: Prefer aspirin monotherapy over DAPT to minimize peri‑operative bleeding risk and coordinate timing with the vascular surgeon or interventionalist【17】.

Bleeding Risk Monitoring

Major bleeding occurs in 0.9 % of patients receiving DAPT versus 0.4 % with aspirin alone over the 21–30 day course【17】.
This equates to roughly 5 extra major bleeds per 1,000 patients treated while preventing 15 ischemic strokes per 1,000 patients【17】.
Consider proton‑pump inhibitor prophylaxis in patients at higher risk for gastrointestinal bleeding【17】.

Evidence Strength and Guideline Recommendations

The Canadian Stroke Best Practice guidelines issue a Level A recommendation for a 21–30 day course of aspirin + clopidogrel in high‑risk TIA patients【17】.

All statements are supported by citation 17 and reflect the current consensus of major stroke societies.

Duration and Safety of Dual Antiplatelet Therapy after Acute Ischemic Stroke

Pathophysiology and Indications

In patients with multiple ischemic strokes affecting different vascular territories, the pattern suggests possible large‑artery atherosclerosis, small‑vessel disease, or cardioembolic etiology. 18

Age‑Related Bleeding Risk

Patients aged ≥ 75 years have a higher risk of intracranial hemorrhage when treated with dual antiplatelet therapy (DAPT). 18

Bleeding Incidence with Short‑Term DAPT

In a 21–30‑day DAPT course, major bleeding occurs in approximately 0.9 % of patients versus 0.4 % with aspirin alone, corresponding to about five additional major bleeds per 1,000 treated individuals. 18

Imaging Findings and Bleeding Risk

Presence of cerebral microhemorrhages on gradient‑echo or susceptibility‑weighted MRI increases the risk of bleeding during DAPT, although it is not an absolute contraindication. 18

Duration Recommendations

Extending DAPT beyond 30 days in routine ischemic‑stroke care is not recommended because the incremental bleeding risk outweighs any uncertain benefit. 18
Continuing DAPT indefinitely after the acute phase is discouraged; the risk‑benefit ratio becomes unfavorable after 21–30 days. 18
Initiating DAPT more than 72 hours after the most recent stroke provides minimal efficacy and should be avoided. 18